Surely DEP-Cabazitaxel would be the perfect drug for Sandoz, who only four months ago lost their patent battle to sell generic Cabazitaxel. Given Sanofi’s Jevtana patent doesn’t expire until 2030, there’d be plenty of time to corner the market in the meantime with a less toxic (and maybe more effective) version, that has wider indications than just prostate cancer.
Come on management, get the deal done.
https://www.fiercepharma.com/pharma/sanofi-blocks-sandoz-jevtana-generic-patent-win
- Forums
- ASX - By Stock
- Ann: Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer
Surely DEP-Cabazitaxel would be the perfect drug for Sandoz, who...
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
9.5¢ |
Change
0.008(9.20%) |
Mkt cap ! $39.14M |
Open | High | Low | Value | Volume |
9.0¢ | 9.5¢ | 8.8¢ | $334.2K | 3.710M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 50354 | 9.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.5¢ | 22908 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 760087 | 0.089 |
2 | 147200 | 0.087 |
3 | 118061 | 0.086 |
3 | 220000 | 0.085 |
1 | 100000 | 0.084 |
Price($) | Vol. | No. |
---|---|---|
0.095 | 22908 | 2 |
0.096 | 5000 | 1 |
0.099 | 6837 | 1 |
0.100 | 71848 | 3 |
0.105 | 370000 | 2 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online